NICE responds to letter on Spinraza access communications

Published Date
Jonathan Kingsley
Spinraza SMA treatment

NICE has responded to the joint letter which was sent by Muscular Dystrophy UK, SMA UK and TreatSMA last month in relation to how NICE and NHS England had communicated decision-making and documents on access to Spinraza since the initial announcement on 15 May.


We had emphasised the effect which this has had on the SMA community.

We were keen to share detailed concerns and feedback to NICE on behalf of the SMA community so that this could be taken on board and acted upon to ensure a constructive and collaborative approach to the forthcoming Managed Access Agreement.

You can read NICE’s response here.

Keep in touch